Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 203

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 203
---
 Stockholders, an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the Plan to 10,206 was approved.

F-18

REVELATION BIOSCIENCES, INC. Notes to the Consolidated Financial Statements 9. Stock-Based Compensation (cont.) Under the 2021 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company’s equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five years from the grant date. As of December 31, 2024, there were 10,142 shares available for future grants under the 2021 Plan. Restricted Stock Units As of December 31, 2024 and December 31, 2023, the Company has a total of 3 Rollover RSU awards for shares of common stock outstanding, respectively. As of December 31, 2024, 3 Rollover RSU awards have fully vested but are unissued and no Rollover RSU awards have been forfeited. Each Rollover RSU award converts to one share of common stock. Stock Options The Company has granted stock options which (i) vest fully on the date of grant; (ii) vest 25% on the one -yearanniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter; or (iii) vest quarterly over one -year, for grants to Board of Directors, officers and employees. Stock options have a maximum term of 3 or 10 years. The activity related to stock options during the year ended December 31, 2024 is summarized as follows:

|                                  |     | Shares |     | Weighted- 
 average   
 Exercise  
 Price     |          |     |   Weighted- 
     average 
   Remaining 
 Contractual 
        Term 
     (Years) |
|:---------------------------------|:----|-------:|:----|:----------|---------:|:----|------------:|
| Outstanding at December 31, 2023 |     |     64 |     | $         | 3,555.83 |     |             |